Back

Interleukin-6 signalling, lipoprotein (a) lowering and cardiovascular disease: a mendelian randomisation study

30 August 2024 (16:35 - 16:45)
Organised by: Logo
Congress Presentation Part of: Dyslipidaemia: novel diagnostics and therapy options Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Stephen Brennan

Mater Misericordiae University Hospital, Dublin (Ireland)

5 More presentations in this session

Presentation thumbnail
Comparative efficacy of colchicine and intensive LDL-C lowering in patients with ASCVD receiving statins: a network meta-analysis of randomised controlled trials
Doctor Z. Ou (Chongqing, CN)
Abstract Slides Video
Presentation thumbnail
Deciphering lipoprotein(a) atherogenicity with use of high-throughput proteomics
Doctor J. Morze (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
The upfront lipid-lowering combination therapy of statins and ezetimibe vs statin monotherapy in the reduction of cardiovascular outcomes. A meta-analysis.
Professor M. Banach (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
Contemporary LDL-cholesterol management in male and female patients at high-cardiovascular risk: results from the European observational SANTORINI study
Professor D. Nanchen (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
The change of paradigm: high HDL-c levels could not mean a long lifespan
Doctor F. Sousa (Funchal, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Dyslipidaemia: novel diagnostics and therapy options
Video

The Event

Event poster

ESC Congress 2024

30 August 2024 16:35 CET
You may be interested in
thumbnail
Congress Presentation
Interleukin-6 and cardiovascular prognosis in apparently healthy individuals
thumbnail
Congress Session
Dyslipidaemia: novel diagnostics and therapy options
thumbnail
Congress Session
Late-Breaking Clinical Science: lipids and cardiovascular risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources